Question 1

What are the specific MAPK pathway mutations that make me eligible for this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations clinical trial (NCT05886920). Contact the study team or your healthcare provider for specific answers.

Question 2

How does D3S-002 compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations clinical trial (NCT05886920). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from D3S-002?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations clinical trial (NCT05886920). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations clinical trial (NCT05886920). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests will I need to undergo before and during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations clinical trial (NCT05886920). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations clinical trial (NCT05886920). Contact the study team or your healthcare provider for specific answers.

What this study is about